VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DSGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DSGNDesign Therapeutics, Inc.
$9.84$591M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDSGNBalance Sheet

Design Therapeutics, Inc. (DSGN) Balance Sheet

7Y historyFree accessUpdated daily

Total assets contracted roughly 20% from $269.6M in 2024Q2 to $216.8M in 2026Q3, with cash of $15.3M and total debt of $2.5M leaving a debt-to-equity ratio of 0.01 that reflects a fully equity-funded structure.

Income StatementBalance SheetCash FlowRatios

DSGN Balance Sheet

Annual statement

DSGN Balance Sheet

Design Therapeutics, Inc. (DSGN) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets213.96M223.78M248.04M284.58M335.12M385.44M36.23M90K
Cash & Short-Term Investments208.61M219.84M245.48M281.8M330.39M384.06M36.09M77K
Cash Only15.25M16.86M22.56M21.2M26.5M298.57M2.38M77K
Short-Term Investments193.36M202.99M222.91M260.6M303.89M85.5M33.71M0
Accounts Receivable1.74M1.68M1.26M1.43M1.11M110K10K0
Days Sales Outstanding--------
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets00000025K8K
Total Non-Current Assets2.85M2.42M4.05M5.06M6.02M5.12M283K0
Property, Plant & Equipment2.85M2.42M3.63M4.63M5.56M5.12M71K0
Fixed Asset Turnover0.00x-------
Goodwill00000000
Intangible Assets00000000
Long-Term Investments00000000
Other Non-Current Assets00427K430K459K0212K0
Total Assets216.81M226.2M252.09M289.64M341.14M390.56M36.52M90K
Asset Turnover0.00x------0.01x
Asset Growth %-14.33%-10.27%-12.96%-15.09%-12.65%969.55%40473.33%-
Total Current Liabilities12.75M13.05M8.46M9.62M10.78M5.28M2.33M3.73M
Accounts Payable2.08M2.31M2.19M1.94M3.02M1.62M1.4M2.48M
Days Payables Outstanding---1.32K2.37K-102.13K547.06K
Short-Term Debt0000000695K
Deferred Revenue (Current)0000000201K
Other Current Liabilities04.63M3.58M4.03M3.54M2.15M565K112K
Current Ratio16.78x17.14x29.31x29.58x31.10x72.96x15.55x0.02x
Quick Ratio16.78x17.14x29.31x29.58x31.10x72.96x15.55x0.02x
Cash Conversion Cycle--------
Total Non-Current Liabilities1.86M645K1.53M2.33M3.05M3.14M45.5M1K
Long-Term Debt0645K000000
Capital Lease Obligations6.73M01.53M2.33M3.05M3.14M00
Deferred Tax Liabilities00000000
Other Non-Current Liabilities00000045.5M1K
Total Liabilities14.61M13.7M10M11.96M13.83M8.43M47.83M3.73M
Total Debt2.51M1.53M2.33M3.05M3.69M3.63M0695K
Net Debt-12.74M-15.32M-20.23M-18.15M-22.81M-294.94M-2.38M618K
Debt / Equity0.01x0.01x0.01x0.01x0.01x0.01x--
Debt / EBITDA-0.03x-------
Net Debt / EBITDA0.16x-------
Interest Coverage--------
Total Equity202.2M212.5M242.1M277.69M327.31M382.13M-11.31M-3.64M
Equity Growth %-20.56%-12.22%-12.82%-15.16%-14.35%3477.2%-210.68%-
Book Value per Share3.213.714.284.965.888.32-0.42-0.13
Total Shareholders' Equity202.2M212.5M242.1M277.69M327.31M382.13M-11.31M-3.64M
Common Stock6K6K6K6K6K6K1K1K
Retained Earnings-355.1M-297.01M-227.21M-177.63M-110.76M-47.46M-11.92M-3.64M
Treasury Stock000000-451K0
Accumulated OCI-1.68M403K475K62K-3.36M-244K156K0
Minority Interest00000000

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Limited cash runway against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Shrinking Asset Base Signals Weakening Position

According to the reported balance sheets, DSGN's total assets declined from $269.6M in 2024Q2 to $216.8M in 2026Q3, a roughly 20% contraction that reflects steady cash consumption rather than any asset-building investment.

The decline in total assets is driven almost entirely by cash depletion, with reported cash falling from $45.7M to $15.3M over the period, which suggests the balance sheet is being run down to fund ongoing development. Shareholders' equity has eroded in parallel, and the accumulated deficit has grown from -$200.5M to -$355.1M, indicating that each quarter's operating losses are permanently reducing the capital base. Investors should view this trajectory as a weakening balance sheet whose strength depends on the timing of the next financing event.

Cash Reserves Thin Relative to Quarterly Burn

Based on reported figures, DSGN held $15.3M in cash at 2026Q3 against free cash flow of roughly -$15.4M in the same quarter, implying cash coverage of about one quarter of current burn.

The current ratio of 16.78 looks comfortable on paper, but it reflects a small liability base rather than a meaningful cash cushion, since the cash balance alone is nearly fully absorbed by a single quarter of operating outflows. The reported cash figure has also fallen in several recent quarters, suggesting the runway is shortening rather than stabilizing. Investors should treat the liquidity position as tight and monitor whether an equity raise or other financing is disclosed before the next reporting period.

Equity Base Eroding Through Accumulated Losses

As reported in the balance sheets, DSGN's equity fell from $261.2M in 2024Q2 to $202.2M in 2026Q3, with retained earnings deficits of -$355.1M absorbing essentially all paid-in capital growth.

Because the company reports no buybacks or dividends and carries a debt-to-equity ratio of only 0.01, the equity decline is a direct function of accumulated operating losses rather than capital returns or leverage effects. The stock-based compensation reported on the income statement partially offsets cash burn but also contributes to dilution over time. Investors should weigh whether future equity issuance, which appears necessary given the cash position, will further dilute existing holders.

Minimal Leverage Reflects Equity-Funded Model

According to reported figures, DSGN carries total debt of $2.5M against $202.2M in equity, a debt-to-equity ratio of 0.01 that indicates development is funded almost entirely through equity rather than borrowing.

The low leverage removes near-term refinancing risk, but it also means the company has no debt capacity to fall back on if equity markets tighten, since its cash-generating ability is negative. The modest debt balance appears to be lease or equipment related rather than a material financing obligation, though its composition is not detailed in the supplied data. Investors should recognize that the lack of debt is a function of the business model rather than a sign of balance sheet strength.

Reported Cash Figures May Understate Urgency

Because the supplied data lacks a current cash balance beyond the 2026Q3 figure, the reported $15.3M may not reflect the most recent liquidity position, and the analysis here rests on a potentially dated snapshot.

If cash reserves have declined further after the latest reported quarter, the runway implied by a single quarter of burn would be even shorter than the figures suggest. Conversely, undisclosed financing arrangements, collaboration payments, or non-dilutive funding could extend the runway, though none are reflected in the provided data and their existence cannot be assumed. Investors should verify current cash and any subsequent financing before drawing firm conclusions about survival timelines.

DSGN — Frequently Asked Questions

Quick answers to the most common questions about buying DSGN stock.

What are the total assets of Design Therapeutics, Inc. (DSGN)?

As of 2025, Design Therapeutics, Inc. (DSGN) had total assets of $226.2M including $223.8M in current assets.

How much debt does Design Therapeutics, Inc. (DSGN) have?

Design Therapeutics, Inc. (DSGN) carries total debt of $1.5M, offset by $219.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Design Therapeutics, Inc.?

Design Therapeutics, Inc. (DSGN) has total shareholders' equity (book value) of $212.5M ($3.71 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Design Therapeutics, Inc.'s current ratio and liquidity?

Design Therapeutics, Inc. (DSGN) reported a current ratio of 17.14x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.